NCT05003986 - Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 12, 2021

Primary Completion Date

March 12, 2027

Study Completion Date

April 12, 2027

Conditions

Focal Segmental GlomerulosclerosisMinimal Change DiseaseImmunoglobulin A NephropathyIgA VasculitisAlport Syndrome

Interventions

DRUG

Sparsentan

Population 1: 800 mg Sparsentan (oral suspension)

DRUG

Sparsentan

Population 2: 400 mg Sparsentan (oral suspension)

DRUG

Sparsentan

Population 3: 400 mg Sparsentan (tablets)

Trial Locations (46)

10016

RECRUITING

Travere Investigational Site, New York

11042

RECRUITING

Travere Investigational Site, New Hyde Park

16147

RECRUITING

Travere Investigational Site, Genova

19104

RECRUITING

Travere Investigational Site, Philadelphia

19134

WITHDRAWN

Travere Investigational Site, Philadelphia

19803

RECRUITING

Travere Investigational Site, Wilmington

20122

RECRUITING

Travere Investigational Site, Milan

20246

RECRUITING

Travere Investigational Site, Hamburg

22710

RECRUITING

Travere Investigational Site, Durham

27599

RECRUITING

Travere Investigational Site, Chapel Hill

28041

RECRUITING

Travere Investigational Site, Madrid

28046

RECRUITING

Travere Investigational Site, Madrid

28203

RECRUITING

Travere Investigational Site, Charlotte

33136

RECRUITING

Travere Investigational Site, Miami

33155

RECRUITING

Travere Investigational Site, Miami

35128

RECRUITING

Travere Investigational Site, Padua

41013

RECRUITING

Travere Investigational Site, Seville

43205

RECRUITING

Travere Investigational Site, Columbus

50937

RECRUITING

Travere Investigational Site, Cologne

52242

WITHDRAWN

Travere Investigational Site, Iowa City

55454

RECRUITING

Travere Investigational Site, Minneapolis

64108

RECRUITING

Travere Investigational Site, Kansas City

69120

RECRUITING

Travere Investigational Site, Heidelberg

70126

RECRUITING

Travere Investigational Site, Bari

73104

RECRUITING

Travere Investigational Site, Oklahoma City

77030

RECRUITING

Travere Investigational Site, Houston

90048

RECRUITING

Travere Investigational Site, Los Angeles

98105

RECRUITING

Travere Investigational Site, Seattle

02111

WITHDRAWN

Travere Investigational Site, Boston

48109-5008

RECRUITING

Travere Investigational Site, Ann Arbor

07601

RECRUITING

Travere Investigational Site, Hackensack

07753

RECRUITING

Travere Investigational Site, Neptune City

00165

RECRUITING

Travere Investigational Site, Roma

1105 AZ

RECRUITING

Travere Investigational Site, Amsterdam

6525 GA

RECRUITING

Travere Investigational Site, Nijmegen

30-663

RECRUITING

Travere Investigational Site, Krakow

93-338

WITHDRAWN

Travere Investigational Site, Lodz

04-730

WITHDRAWN

Travere Investigational Site, Warsaw

08035

RECRUITING

Travere Investigational Site, Barcelona

416 85

RECRUITING

Travere Investigational Site, Gothenburg

141 86

RECRUITING

Travere Investigational Site, Stockholm

BS2 8BJ

RECRUITING

Travere Investigational Site, Bristol

G51 4TF

RECRUITING

Travere Investigational Site, Glasgow

L12 2AP

RECRUITING

Travere Investigational Site, Liverpool

WC1N3JH

RECRUITING

Travere Investigational Site, London

M13 9WL

RECRUITING

Travere Investigational Site, Manchester

All Listed Sponsors

lead

Travere Therapeutics, Inc.

INDUSTRY